We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

DIESSE DIAGNOSTICA SENESE SPA

DIESSE Diagnostica Senese S.P.A. manufactures in-vitro diagnostics systems for the hematology, seroimmunology and bac... read more Featured Products: More products

Download Mobile App





DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

By LabMedica International staff writers
Posted on 25 May 2023
Print article
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)

Diesse Diagnostica Senese S.p.A. (Rigoni, Italy) is unveiling its new innovative immunochemistry analyzer, the CHORUS EVO, at this year's WorldLab-EuroMedLab.

The cutting-edge DIESSE CHORUS line comprises a compact instrument and consumables for immunometric assays. Known for simplicity, high-quality mono-test results, and reliability, the CHORUS line is the perfect tool for conducting small-batch diagnostic tests. Its design ensures maximum flexibility in managing the workflow of a clinical laboratory. Even when lab automation isn't viable, the CHORUS line stands out as a go-to solution for immediate, simple, and accurate testing. Its mono-test format facilitates operational efficiency and minimal waste, which is a boon for smaller test volumes. This makes CHORUS an excellent resource for Physician Office Laboratories (POLs) and other diagnostic laboratories, providing them with analytical quality and operational efficiency.

In line with developing instruments featuring cutting-edge technology that meet Italian design and its vision of "Diagnostics Evolution", DIESSE has now unveiled the CHORUS EVO immunochemistry analyzer. CHORUS EVO is a new-generation analytical instrument that integrates innovative digital technology, paving the way for the integration of artificial intelligence functions. In order to achieve this, DIESSE is collaborating with the SAIHUB consortium, a network of companies that specialize in applying artificial intelligence in life sciences.

Their collaborative effort is directed towards creating a data platform, to which the instruments will be connected, facilitating a large-scale data accumulation. This setup will enable direct digital communication between the company and individual instruments, making it possible for the company to monitor the instruments through the data platform. Moreover, it will harness beneficial artificial intelligence functions to train the analyzers to enhance their performance and employ predictive diagnostics to preempt machine downtime. The project also plans to incorporate computer vision systems rooted in artificial intelligence to further optimize the diagnostic capabilities of the instruments.

Related Links:
Diesse Diagnostica Senese Spa

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.